Sano Healthcare Consultants, LLC

Sano Healthcare Consultants, LLC, a black American-owned, minority-owned limited liability company headquartered in Ontario, California, develops medical device technologies for substance use disorder and chronic disease management as a federal grant recipient. The vendor operates exclusively as a prime recipient on National Institutes of Health grants, with no federal contract prime or subcontractor activity in the source data.

Sano's federal grant portfolio centers on innovations in medication adherence monitoring and remote dispensing. The vendor holds two active grants from the National Institute on Drug Abuse totaling $2.6 million in combined obligations: a project grant awarded August 1, 2024, with ultimate completion July 31, 2028, funding development of secure remote dispensing technology for liquid methadone with home monitoring using environmental interactive devices and quality-of-care utilization coding systems designed to improve access and outcomes for opioid use disorder treatment; and a second project grant awarded August 1, 2024, with completion July 31, 2025, advancing a novel liquid methadone dispensing device and smart container with Wi-Fi and Bluetooth capability for remote video observed therapy. A third grant from the National Institute on Aging, awarded February 15, 2023, with completion January 31, 2024, supported development of a smart pill container and cap technology to improve medication adherence in stroke survivors, addressing health disparities through single-hand accessibility and dual in-home dosing alerts with adherence monitoring via gravimetric and weight-sensor systems.

Sano's customer base is concentrated within two divisions of the National Institutes of Health—the National Institute on Drug Abuse holds two awards and the National Institute on Aging holds one—representing 100% of the vendor's recent award footprint. One grant completes within the next twenty-four months, exposing Sano to recompete activity in that window. The vendor's federal presence is narrowly focused on early-stage medical device development for health disparity reduction, with no parent contract vehicles, teaming relationships, or subcontractor roles evident in the source data.